Paper11259554
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
Hatzelmann A and 1 other. J Pharmacol Exp Ther, 2001. Cited by 323 papers, by iCite.
Cite this record
ConductScience Library. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. Papers, record 11259554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11259554
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
- PubMed
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| 3',5'-Cyclic-AMP Phosphodiesterases | Major topic |
| Anti-Inflammatory Agents, Non-Steroidal | Major topic |
| Immunosuppressive Agents | Major topic |
| Phosphodiesterase Inhibitors | Major topic |
| Aminopyridines | |
| Benzamides | |
| CD4-Positive T-Lymphocytes | |
| Cyclic Nucleotide Phosphodiesterases, Type 1 | |
| Cyclic Nucleotide Phosphodiesterases, Type 4 | |
| Cyclopropanes | |
| Cytokines | |
| Dendritic Cells | |
| Eosinophils | |
| Humans | |
| In Vitro Techniques | |
| Luminescent Measurements | |
| Lymphocyte Activation | |
| Monocytes | |
| Neutrophils | |
| Pyridazines | |
| Tumor Necrosis Factor-alpha |
Source PubMed
Cited by118
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 323 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42897680 | Roflumilast mitigates cartilage degeneration in osteoarthritis by activating CFTR-mediated anti-apoptotic signaling. | Arthritis Res Ther | 2026 | https://conductscience.org/library/papers/42897680 | PubMed |
| 42368799 | Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database. | Front Psychiatry | 2026 | https://conductscience.org/library/papers/42368799 | PubMed |
| 42181088 | Practical considerations for managing patients being treated with topical roflumilast. | J Pharm Pharm Sci | 2026 | https://conductscience.org/library/papers/42181088 | PubMed |
| 41787480 | A small‑molecule HDAC/PDE modulator activates human adipocyte UCP1 and resolves inflammatory signaling. | J Transl Med | 2026 | https://conductscience.org/library/papers/41787480 | PubMed |
| 41594619 | Trends in Inhibitors, Structural Modifications, and Structure-Function Relationships of Phosphodiesterase 4: A Review. | Biomolecules | 2026 | https://conductscience.org/library/papers/41594619 | PubMed |
| 40783516 | Comparison of cilomilast, tadalafil, and both drug combinations in the treatment of monocrotaline-induced pulmonary arterial hypertension in rats. | BMC Cardiovasc Disord | 2025 | https://conductscience.org/library/papers/40783516 | PubMed |
| 40358183 | Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy. | Cells | 2025 | https://conductscience.org/library/papers/40358183 | PubMed |
| 40276862 | Effectiveness and safety of topical phosphodiesterase 4 inhibitors in children with mild-to-moderate atopic dermatitis: A systematic review and meta-analysis. | J Int Med Res | 2025 | https://conductscience.org/library/papers/40276862 | PubMed |
| 40192433 | Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis Models. | Acta Derm Venereol | 2025 | https://conductscience.org/library/papers/40192433 | PubMed |
| 40081105 | Cyclic nucleotide phosphodiesterases as drug targets. | Pharmacol Rev | 2025 | https://conductscience.org/library/papers/40081105 | PubMed |
| 39942796 | Molecular Properties of Phosphodiesterase 4 and Its Inhibition by Roflumilast and Cilomilast. | Molecules | 2025 | https://conductscience.org/library/papers/39942796 | PubMed |
| 39679247 | Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats. | Int J Nanomedicine | 2024 | https://conductscience.org/library/papers/39679247 | PubMed |
| 39223490 | Phosphodiesterase 4 is overexpressed in keloid epidermal scars and its inhibition reduces keratinocyte fibrotic alterations. | Mol Med | 2024 | https://conductscience.org/library/papers/39223490 | PubMed |
| 38807127 | MnO2 and roflumilast-loaded probiotic membrane vesicles mitigate experimental colitis by synergistically augmenting cAMP in macrophage. | J Nanobiotechnology | 2024 | https://conductscience.org/library/papers/38807127 | PubMed |
| 38688656 | The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice. | In Vivo | 2024 | https://conductscience.org/library/papers/38688656 | PubMed |
| 36813290 | Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis. | Eur Respir Rev | 2023 | https://conductscience.org/library/papers/36813290 | PubMed |
| 35942000 | Longstanding hypersensitivity pneumonitis and its response to roflumilast: A review of its likely immunological effects. | Respir Med Case Rep | 2022 | https://conductscience.org/library/papers/35942000 | PubMed |
| 35517783 | BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35517783 | PubMed |
| 35163131 | Clinical Implication of Phosphodiesterase-4-Inhibition. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35163131 | PubMed |
| 35057082 | The Compound (E)-2-Cyano-N,3-diphenylacrylamide (JMPR-01): A Potential Drug for Treatment of Inflammatory Diseases. | Pharmaceutics | 2022 | https://conductscience.org/library/papers/35057082 | PubMed |
Genes9
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CD28 | 940 | PubTator's text mining | https://conductscience.org/library/genes/940 | NCBI Gene |
| CD4 | 920 | PubTator's text mining | https://conductscience.org/library/genes/920 | NCBI Gene |
| IFNG | 3458 | PubTator's text mining | https://conductscience.org/library/genes/3458 | NCBI Gene |
| IL2 | 3558 | PubTator's text mining | https://conductscience.org/library/genes/3558 | NCBI Gene |
| IL4 | 3565 | PubTator's text mining | https://conductscience.org/library/genes/3565 | NCBI Gene |
| IL5 | 3567 | PubTator's text mining | https://conductscience.org/library/genes/3567 | NCBI Gene |
| PDE4A | 5141 | PubTator's text mining | https://conductscience.org/library/genes/5141 | NCBI Gene |
| PDE5A | 8654 | PubTator's text mining | https://conductscience.org/library/genes/8654 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/11259554
GET https://conductscience.org/api/papers/v1/11259554/cited_by?page=2